Loading market information…
SHZ · 300558.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Betta Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Betta Pharmaceuticals Co., Ltd.’s forward annual dividend is CN¥0.15 per share, paid annual. The forward yield is 0.37% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Betta Pharmaceuticals Co., Ltd.’s next earnings report is currently expected on Apr 28, 2027, with estimated earnings per share of CN¥0.28. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Betta Pharmaceuticals Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Betta Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of oncology treatments. Among its key offerings are Icotinib hydrochloride, an orally taken epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and Ensartinib hydrochloride, an anaplastic lymphoma kinase (ALK) inhibitor, both utilized in the management of non-small-cell lung cancer. Founded in 2003, the firm is headquartered in Hangzhou, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥986.00M+14.16% vs estimate |
| Q2 2025 | Aug 19, 2025 | CN¥0.10-74.36% vs estimate | CN¥811.93M-12.56% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | CN¥0.24-46.67% vs estimate | CN¥918.00M+13.45% vs estimate |
|---|
| Q1 2025 | Apr 17, 2025 | -CN¥0.03-107.89% vs estimate | CN¥547.00M-27.65% vs estimate |
|---|
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
